Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy (Q34541113)

From Wikidata

Jump to navigation Jump to search

scientific article

edit

Language	Label	Description	Also known as
English	Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy	scientific article

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21244693

retrieved

2 August 2017

title

Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21244693

retrieved

2 August 2017

main subject

patient

0 references

antibody

1 reference

based on heuristic

inferred from title

immunotherapy

1 reference

based on heuristic

inferred from title

chemotherapy

1 reference

based on heuristic

inferred from title

neuroblastoma

1 reference

based on heuristic

inferred from title

author

Martin Schrappe

series ordinal

5

object named as

Martin Schrappe

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21244693

retrieved

2 August 2017

Thomas Klingebiel

series ordinal

6

object named as

Thomas Klingebiel

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21244693

retrieved

2 August 2017

author name string

Thorsten Simon

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21244693

retrieved

2 August 2017

Barbara Hero

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21244693

retrieved

2 August 2017

Andreas Faldum

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21244693

retrieved

2 August 2017

Rupert Handgretinger

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21244693

retrieved

2 August 2017

Frank Berthold

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21244693

retrieved

2 August 2017

language of work or name

English

0 references

publication date

18 January 2011

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21244693

retrieved

2 August 2017

published in

BMC Cancer

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21244693

retrieved

2 August 2017

volume

11

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21244693

retrieved

2 August 2017

page(s)

21

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21244693

retrieved

2 August 2017

cites work

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031264

retrieved

7 July 2018

Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031264

retrieved

7 July 2018

High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031264

retrieved

7 July 2018

Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031264

retrieved

7 July 2018

Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031264

retrieved

7 July 2018

Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031264

retrieved

7 July 2018

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031264

retrieved

7 July 2018

Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031264

retrieved

7 July 2018

A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031264

retrieved

7 July 2018

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031264

retrieved

7 July 2018

Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3031264

retrieved

7 July 2018

Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1186%2F1471-2407-11-21

retrieved

21 January 2018

Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21244693

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21244693

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21244693

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21244693

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21244693

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21244693

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21244693

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21244693

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1186/1471-2407-11-21

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21244693

retrieved

2 August 2017

Dimensions Publication ID

1046480488

0 references

PMC publication ID

3031264

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21244693

retrieved

2 August 2017

PubMed publication ID

21244693

1 reference

stated in

Europe PubMed Central

PubMed publication ID

21244693

retrieved

2 August 2017

ResearchGate publication ID

49764685

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34541113&oldid=2196756788"